Earnings ·
Reports $69.3M revenue for nine months ended Sept 30, 2026
SOPHSOPHiA GENETICS SA
SOPHiA GENETICS SA reported unaudited financial results for the three and nine months ended September 30, 2026. Revenue increased 25% to $69.3 million from $55.6 million in the prior-year period, driven by a 19% rise in platform analysis volume and strong growth in oncology applications. The company posted a net loss of $62.0 million for the nine-month period, compared to $59.8 million previously. Cash and cash equivalents rose to $93.7 million from $70.3 million at year-end 2025, supported by $53.1 million in net proceeds from a public equity offering and $15.7 million from an ATM program. The company also noted continued litigation with Guardant Health regarding patent infringement claims. SOPHiA GENETICS SA operates as a cloud-native software technology company providing data-driven medicine solutions for healthcare and life sciences research.